Aesica, the global contract development and manufacturing organisation (CDMO), has today announced the appointment of Baali Muganga to the role of East Coast U.S. Business Development Manager. Central to the new role is responsibility for expanding the share of the company’s east coast North American contract development manufacturing market in pharmaceuticals.
In terms of US focused expertise, Baali brings in excess of five years new business experience gained across the life sciences industry. Key roles have included business development, commercial operations and clinical and bioinformatics research. Recently, she served in the role of Associate Alliance Manager with Reata Pharmaceuticals, a Dallas-based biopharmaceutical company. Prior to this, she worked at AstraZeneca and the Children’s Hospital of Philadelphia. She received a B.A. degree in Biological Basis of Behavior from the University of Pennsylvania.
Specifically, Baali Muganga will be responsible for targeting small to medium sized life science and pharmaceutical companies requiring product development and manufacturing support. As a two pronged strategic approach, Baali will have responsibility for expanding business from existing customers, as well as securing new client wins for the Group.
Aesica is also pleased to announce the engagement of Julius Lodato as Aesica LLC’s Director of Finance and Administration in order to support the growing US office. Julius is a highly experienced CPA with a Masters in taxation. Previous roles include a tenure at DSM Pharma. Emma Mickley stated: “We are very pleased that Julius has joined our team. His understanding of the contract pharmaceutical and manufacturing market will be pivotal in the continued growth of Aesica’s operations in the US and North America”.
Commenting on Baali Muganga’s appointment, Emma Mickley, VP, Corporate Business Development at Aesica commented: “We are delighted to have Baali Muganga join the Aesica sales force. We look forward to leveraging her expertise gained through working for companies like Reata Pharmaceuticals and AstraZeneca, to help expand our presence across North America.”
She continued: “To date Aesica has successfully established many key partnerships in North America, and the intended acquisition of a development and manufacturing centre in this region will enable us to provide even greater levels of service to existing and new clients.”
“We have a strong international track record for service excellence, with an individualised and highly flexible service model, and an extensive range of services across API manufacture, formulation development and formulated products. As such we look forward to bringing significantly more of what we offer to the US market as we continue to build our USA footprint.”